A promising step has been taken in the treatment of glaucoma, a condition that causes damage to the optic nerve and can lead to loss of vision. The company Life Biosciences has launched a clinical trial with an innovative therapy that attempts to ‘rejuvenate’ cells in the eye. This approach is called partial epigenetic reprogramming.
With this technique, cells are temporarily exposed to special substances, the so-called Yamanaka factors, which cause the cells to appear less aged. It is a precise method in which the balance between rejuvenation and the preservation of the original cell function is important. The goal is to repair damaged cells in the optic nerve without losing their special properties.
The therapy is administered via a virus that acts as a ‘delivery agent’ and delivers the therapeutic agent directly into the eye. This virus is harmless and ensures that the treatment can be administered for an extended period. Moreover, the therapy can be turned on and off using an antibiotic, allowing doctors to properly adjust the dosage.
The first results from the human study appear promising. In animal studies, the function of a damaged optic nerve has already been successfully restored. This could in the future mean that patients with glaucoma or other eye problems can maintain better vision and prevent further loss of sight.
This new technique shows that tissue rejuvenation with targeted cell treatment is becoming more practical, which is important for anyone who wants to become healthier as they age and maintain their senses.
Source: Reason
